Sotorasib (AMG 510), an experimental small molecule which irreversibly binds G12C, has been granted breakthrough therapy designation by US FDA for the treatment of patients with locally advanced or metastatic NSCLC with KRAS G12C mutation. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.